{"id":"W2017709949","doi":"10.1160/th12-03-0209","title":"Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor","year":2012,"lang":"en","type":"review","venue":"Thrombosis and Haemostasis","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Allergan; Bayer HealthCare; Pfizer","keywords":"Rivaroxaban; Apixaban; Medicine; Dabigatran; Clinical trial; Discovery and development of direct thrombin inhibitors; Direct thrombin inhibitor; Intensive care medicine; Atrial fibrillation; Deep vein; Stroke (engine); Thrombosis; Venous thrombosis; Warfarin; Surgery; Internal medicine; Thrombin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005066733,0.0007092278,0.003353087,0.0002322104,0.0002917098,0.0001117437,0.0002842031,0.0002716746,0.000173317],"category_scores_gemma":[0.00005967139,0.0004442317,0.0007185987,0.0003192651,0.000304396,0.0001335087,0.0002811095,0.0002202131,0.00001544996],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001096982,"about_ca_system_score_gemma":0.00007101423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002378479,"about_ca_topic_score_gemma":0.000036437,"domain_scores_codex":[0.9970526,0.0001782229,0.001022179,0.0006963991,0.0004253749,0.0006252557],"domain_scores_gemma":[0.9970711,0.00062485,0.0006417818,0.001229115,0.0001537085,0.0002794143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002938963,0.0007831785,0.00004353607,0.02107972,0.003098908,0.000003242178,0.0002016046,6.04791e-7,0.000001765242,0.001036635,0.02653633,0.9471851],"study_design_scores_gemma":[0.0007219103,0.0003556153,0.001398996,0.006366856,0.01604835,0.000006783004,0.00009732455,0.00001010746,0.00003539469,0.00001053823,0.9744837,0.0004643901],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006813095,0.9910486,0.00006441226,0.0004149834,0.0006005846,0.005675585,0.001008161,0.0000859075,0.0004204469],"genre_scores_gemma":[0.0009036321,0.9926498,0.004451818,0.0003109918,0.0002999632,0.000696044,0.0001858403,0.0001427343,0.0003591624],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9479474,"threshold_uncertainty_score":0.9998009,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.348422928205051,"score_gpt":0.4101086491624937,"score_spread":0.06168572095744268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}